BUENA, N.J., June 20, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted two additional abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions in 2014 to six, with seventeen submissions now pending at the FDA.
Jason Grenfell-Gardner, President and CEO of the Company, commented, "Our team has filed five ANDAs this week alone, including the ANDA we announced earlier today under a partnership with Impax Laboratories, Inc. We set expectations for our team extremely high, and they have proven they can deliver. We now have seventeen ANDAs pending approval and on file with the FDA, in addition to four more ANDAs pending approval under joint development agreements with our partners. Our 2014 goal of at least ten ANDA submissions remains on track. We believe our current pipeline of submissions pending approval by the FDA has a combined addressable market of over $465 million based on recent data from IMS Health."
About IGI Laboratories, Inc.
IGI Laboratories is a generic topical pharmaceutical company. We develop and manufacture topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market.
For further information:
Jenniffer Collins
IGI Laboratories, Inc.
(856) 697-4379
www.igilabs.com